{
  "ticker": "FRE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961061",
  "id": "02961061",
  "pages": 20,
  "price_sensitive": false,
  "date": "20250623",
  "time": "1506",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06l0kp5csl810l.pdf",
  "summary": "No material information identified (Investor Presentation with no new capital/operational updates or trading-sensitive disclosures).  \n\nKey non-price-sensitive points for context only:  \n- Marketing shift - Nasodine now positioned as nasal antiseptic (not just cold treatment) to lower regulatory barriers  \n- Launched in US (online), Singapore, Fiji; Philippines filing expected Sep 2025  \n- Peer-reviewed study published June 2025 (based on 2019 trial) showing symptomatic benefit when used early  \n- FY26 plans: Scale US online sales, SE Asia expansion, potential new product launches  \n\nNote: Presentation contains forward-looking statements without concrete financial/timetable commitments. No capital raising, financial results, or material agreements announced.",
  "usage": {
    "prompt_tokens": 4615,
    "completion_tokens": 147,
    "total_tokens": 4762,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-23T05:52:53.694710"
}